Serious adverse events
|
S95005 |
Total subjects affected by serious adverse events
|
|
subjects affected / exposed
|
335 / 914 (36.65%) |
number of deaths (all causes)
|
87 |
number of deaths resulting from adverse events
|
3 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
Cancer pain
|
|
subjects affected / exposed
|
9 / 914 (0.98%) |
occurrences causally related to treatment / all
|
0 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
Intracranial tumour haemorrhage
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Malignant ascites
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Malignant neoplasm progression
|
|
subjects affected / exposed
|
124 / 914 (13.57%) |
occurrences causally related to treatment / all
|
3 / 124 |
deaths causally related to treatment / all
|
2 / 54 |
Malignant pleural effusion
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to biliary tract
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to bladder
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to bone
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to central nervous system
|
|
subjects affected / exposed
|
20 / 914 (2.19%) |
occurrences causally related to treatment / all
|
0 / 20 |
deaths causally related to treatment / all
|
0 / 3 |
Metastases to kidney
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to liver
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to lung
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 3 |
Metastases to muscle
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to peritoneum
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to pleura
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Metastases to retroperitoneum
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to spine
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Tumour associated fever
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastasis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tumour compression
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Vascular disorders
|
|
Aortic aneurysm
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Hypertension
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Deep vein thrombosis
|
|
subjects affected / exposed
|
6 / 914 (0.66%) |
occurrences causally related to treatment / all
|
1 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
Jugular vein thrombosis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypotension
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Thrombosis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
General disorders and administration site conditions
|
|
Asthenia
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
2 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Death
|
|
subjects affected / exposed
|
5 / 914 (0.55%) |
occurrences causally related to treatment / all
|
1 / 5 |
deaths causally related to treatment / all
|
1 / 5 |
Chest pain
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Fatigue
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Generalised oedema
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
General physical health deterioration
|
|
subjects affected / exposed
|
20 / 914 (2.19%) |
occurrences causally related to treatment / all
|
3 / 20 |
deaths causally related to treatment / all
|
0 / 8 |
Multiple organ dysfunction syndrome
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Oedema peripheral
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Pyrexia
|
|
subjects affected / exposed
|
8 / 914 (0.88%) |
occurrences causally related to treatment / all
|
2 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
Systemic inflammatory response syndrome
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Reproductive system and breast disorders
|
|
Perineal induration
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Prostatitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
Bronchospasm
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Acute respiratory failure
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Bronchopleural fistula
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Dyspnoea
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
Epistaxis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Haemoptysis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Interstitial lung disease
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pleural effusion
|
|
subjects affected / exposed
|
8 / 914 (0.88%) |
occurrences causally related to treatment / all
|
0 / 8 |
deaths causally related to treatment / all
|
0 / 3 |
Pulmonary embolism
|
|
subjects affected / exposed
|
10 / 914 (1.09%) |
occurrences causally related to treatment / all
|
2 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
Pulmonary infarction
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pulmonary oedema
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Respiratory distress
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Respiratory failure
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Psychiatric disorders
|
|
Anxiety disorder
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Confusional state
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Delirium tremens
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Delirium
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hallucination
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Product issues
|
|
Device occlusion
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Investigations
|
|
Alanine aminotransferase increased
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Aspartate aminotransferase increased
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Blood alkaline phosphatase increased
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Blood creatinine increased
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gamma-glutamyltransferase increased
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Neutrophil count decreased
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Platelet count decreased
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Weight decreased
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Injury, poisoning and procedural complications
|
|
Anaemia postoperative
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bladder injury
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Facial bones fracture
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Fall
|
|
subjects affected / exposed
|
5 / 914 (0.55%) |
occurrences causally related to treatment / all
|
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Femur fracture
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lumbar vertebral fracture
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Incision site haematoma
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Upper limb fracture
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary tract stoma complication
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Vascular access malfunction
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Cardiac disorders
|
|
Acute myocardial infarction
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Atrial fibrillation
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Pericardial effusion
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 2 |
Myocardial infarction
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tachycardia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Nervous system disorders
|
|
Coma hepatic
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Apraxia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cauda equina syndrome
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Dizziness
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Epilepsy
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Headache
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Haemorrhage intracranial
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Febrile convulsion
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Neuralgia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Loss of consciousness
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Intracranial aneurysm
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Status epilepticus
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Neuropathy peripheral
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Sciatica
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Syncope
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Transient ischaemic attack
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vertigo CNS origin
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Blood and lymphatic system disorders
|
|
Anaemia
|
|
subjects affected / exposed
|
34 / 914 (3.72%) |
occurrences causally related to treatment / all
|
28 / 37 |
deaths causally related to treatment / all
|
0 / 0 |
Blood loss anaemia
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Anaemia of malignant disease
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
Bone marrow failure
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Febrile bone marrow aplasia
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Febrile neutropenia
|
|
subjects affected / exposed
|
9 / 914 (0.98%) |
occurrences causally related to treatment / all
|
10 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
Microcytic anaemia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Leukopenia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lymphopenia
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Pancytopenia
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Neutropenia
|
|
subjects affected / exposed
|
20 / 914 (2.19%) |
occurrences causally related to treatment / all
|
25 / 25 |
deaths causally related to treatment / all
|
0 / 0 |
Thrombocytopenia
|
|
subjects affected / exposed
|
5 / 914 (0.55%) |
occurrences causally related to treatment / all
|
4 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Eye disorders
|
|
Blindness unilateral
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Retinal artery thrombosis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal disorders
|
|
Abdominal hernia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Abdominal incarcerated hernia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Abdominal pain
|
|
subjects affected / exposed
|
12 / 914 (1.31%) |
occurrences causally related to treatment / all
|
2 / 13 |
deaths causally related to treatment / all
|
0 / 1 |
Abdominal pain upper
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Abdominal pain lower
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Abdominal strangulated hernia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ascites
|
|
subjects affected / exposed
|
11 / 914 (1.20%) |
occurrences causally related to treatment / all
|
0 / 11 |
deaths causally related to treatment / all
|
0 / 2 |
Anal haemorrhage
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Constipation
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Colitis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Diarrhoea
|
|
subjects affected / exposed
|
11 / 914 (1.20%) |
occurrences causally related to treatment / all
|
11 / 12 |
deaths causally related to treatment / all
|
1 / 1 |
Dysphagia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Enteritis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Faecaloma
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Gastric stenosis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal haemorrhage
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal obstruction
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal toxicity
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Haemorrhoidal haemorrhage
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ileus paralytic
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ileus
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Impaired gastric emptying
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Intestinal obstruction
|
|
subjects affected / exposed
|
16 / 914 (1.75%) |
occurrences causally related to treatment / all
|
2 / 16 |
deaths causally related to treatment / all
|
0 / 3 |
Intestinal perforation
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Large intestinal stenosis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Malignant gastrointestinal obstruction
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
Mouth ulceration
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Obstruction gastric
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Nausea
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
2 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Oesophageal varices haemorrhage
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pancreatic failure
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pancreatitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Peritoneocutaneous fistula
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Stomatitis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Subileus
|
|
subjects affected / exposed
|
6 / 914 (0.66%) |
occurrences causally related to treatment / all
|
2 / 6 |
deaths causally related to treatment / all
|
0 / 1 |
Varices oesophageal
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vomiting
|
|
subjects affected / exposed
|
14 / 914 (1.53%) |
occurrences causally related to treatment / all
|
8 / 16 |
deaths causally related to treatment / all
|
1 / 2 |
Hepatobiliary disorders
|
|
Bile duct obstruction
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bile duct stenosis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cholangitis
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Biliary dilatation
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Cholecystitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cholestasis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cholecystitis acute
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hepatic failure
|
|
subjects affected / exposed
|
10 / 914 (1.09%) |
occurrences causally related to treatment / all
|
2 / 10 |
deaths causally related to treatment / all
|
1 / 4 |
Mixed liver injury
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Jaundice
|
|
subjects affected / exposed
|
10 / 914 (1.09%) |
occurrences causally related to treatment / all
|
0 / 10 |
deaths causally related to treatment / all
|
0 / 3 |
Portal hypertension
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Renal and urinary disorders
|
|
Chronic kidney disease
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Acute kidney injury
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
1 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
Calculus urinary
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Haematuria
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Hydronephrosis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Nephropathy toxic
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Proteinuria
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Renal failure
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary retention
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
Arthritis reactive
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Back pain
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Bone pain
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Musculoskeletal pain
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Osteoarthritis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pathological fracture
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Infections and infestations
|
|
Abdominal sepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Abdominal wall abscess
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Anal abscess
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Aspergilloma
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bacterial pyelonephritis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bacterial sepsis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
Biliary tract infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Biliary sepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bronchitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cellulitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cellulitis gangrenous
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Clostridium difficile colitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cystitis escherichia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Device related infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cytomegalovirus colitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Endophthalmitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Escherichia pyelonephritis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Escherichia sepsis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Gastroenteritis viral
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Escherichia urinary tract infection
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Infective exacerbation of chronic obstructive airways disease
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Listeria sepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Liver abscess
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lower respiratory tract infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Lymphangitis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Medical device site infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Muscle abscess
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Neutropenic sepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pelvic abscess
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
Pneumonia
|
|
subjects affected / exposed
|
21 / 914 (2.30%) |
occurrences causally related to treatment / all
|
4 / 21 |
deaths causally related to treatment / all
|
0 / 3 |
Pneumonia pseudomonal
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pneumonia staphylococcal
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Postoperative wound infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Psoas abscess
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pyelonephritis
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Pyelonephritis acute
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pyopneumothorax
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Respiratory tract infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Sepsis
|
|
subjects affected / exposed
|
5 / 914 (0.55%) |
occurrences causally related to treatment / all
|
1 / 5 |
deaths causally related to treatment / all
|
0 / 1 |
Septic shock
|
|
subjects affected / exposed
|
4 / 914 (0.44%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 2 |
Spinal cord infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Staphylococcal sepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Stenotrophomonas sepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Subcutaneous abscess
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tracheobronchitis bacterial
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary tract infection
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Urosepsis
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary tract infection staphylococcal
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vascular device infection
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Metabolism and nutrition disorders
|
|
Cachexia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Decreased appetite
|
|
subjects affected / exposed
|
5 / 914 (0.55%) |
occurrences causally related to treatment / all
|
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Dehydration
|
|
subjects affected / exposed
|
8 / 914 (0.88%) |
occurrences causally related to treatment / all
|
4 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
Hypocalcaemia
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypoalbuminaemia
|
|
subjects affected / exposed
|
2 / 914 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Hypokalaemia
|
|
subjects affected / exposed
|
3 / 914 (0.33%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Malnutrition
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Steroid diabetes
|
|
subjects affected / exposed
|
1 / 914 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |